| 2023年年报 | 2023年中报 | 2022年年报 | 2022年中报 | |
|---|---|---|---|---|
| 营业收入(元) | ||||
| 临床试验(元) | 142,630,215.02 | 66,636,927.08 | 135,891,117.56 | 60,402,213.11 |
| 医药研发(元) | 191,817,549.45 | 82,584,001.00 | 183,772,506.47 | 81,731,555.52 |
| 租赁及物业服务(元) | 27,645,364.72 | 12,885,722.24 | 22,441,698.89 | 15,874,392.01 |
| 其他收入(元) | 4,121,924.90 | 2,559,619.66 | 4,268,841.64 | 2,467,787.62 |
| 其他业务(元) | - | - | - | 3,286,796.28 |
| 营业成本(元) | ||||
| 临床试验(元) | 104,157,852.23 | 46,621,141.46 | 105,426,790.40 | 47,679,501.14 |
| 医药研发(元) | 78,429,955.40 | 39,878,083.29 | 100,941,078.13 | 45,849,278.69 |
| 租赁及物业服务(元) | - | - | - | - |
| 其他收入(元) | 5,595,888.47 | 2,500,136.22 | 3,847,382.59 | 2,170,413.32 |
| 其他业务(元) | - | - | - | 3,747.28 |
| 毛利(元) | ||||
| 临床试验(元) | 38,472,362.79 | 20,015,785.62 | 30,464,327.16 | 12,722,711.97 |
| 医药研发(元) | 113,387,594.05 | 42,705,917.71 | 82,831,428.34 | 35,882,276.83 |
| 租赁及物业服务(元) | 27,645,364.72 | 12,885,722.24 | 22,441,698.89 | - |
| 其他收入(元) | -1,473,963.57 | 59,483.44 | 421,459.05 | 297,374.30 |
| 其他业务(元) | - | - | - | 3,283,049.00 |
| 毛利率(%) | ||||
| 临床试验(%) | 26.97 | 30.04 | 22.42 | 21.06 |
| 医药研发(%) | 59.11 | 51.71 | 45.07 | 43.90 |
| 租赁及物业服务(%) | - | - | - | - |
| 其他收入(%) | -35.76 | 2.32 | 9.87 | 12.05 |
| 其他业务(%) | - | - | - | 99.89 |
| 收入构成(%) | ||||
| 临床试验(%) | 38.95 | 40.47 | 39.23 | 36.88 |
| 医药研发(%) | 52.38 | 50.15 | 53.06 | 49.91 |
| 租赁及物业服务(%) | 7.55 | 7.83 | 6.48 | 9.69 |
| 其他收入(%) | 1.13 | 1.55 | 1.23 | 1.51 |
| 其他业务(%) | - | - | - | 2.01 |
| 毛利构成(%) | ||||
| 临床试验(%) | 21.61 | 26.45 | 22.37 | 24.38 |
| 医药研发(%) | 63.69 | 56.44 | 60.83 | 68.76 |
| 租赁及物业服务(%) | 15.53 | 17.03 | 16.48 | 0.00 |
| 其他收入(%) | -0.83 | 0.08 | 0.31 | 0.57 |
| 其他业务(%) | - | - | - | 6.29 |